Clinical trials: Human Cancers
Solid Tumor Cancer
A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
This is a Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Participants with Advanced Solid Tumors.
- Trial name
- NCT06934616
- Testing
- GB268
- Volunteers
- 330 people
- Sponsor
- Genor Biopharma Co., Ltd.
Anemia, Neoplasms
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)
The main purpose of this study is to evaluate the safety and efficacy (% response) of epoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer.
- Trial name
- NCT00398749
- Testing
- Epoetin alfa
- Volunteers
- 1,927 people
- Sponsor
- Janssen-Cilag B.V.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in patients receiving chemotherapy for acute…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia
- Trial name
- NCT01297543
- Testing
- human myeloid progenitor cells, G-CSF
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cellerant Therapeutics
Astrocytoma, Grade IV, Giant Cell Glioblastoma
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide
- Trial name
- CYNK001GBM01 (NCT04489420)
- Testing
- CYNK001-IV, CYNK001-IT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Celularity Incorporated
Malignant Melanoma
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.
- Trial name
- NCT00111696
- Testing
- MEDI-522
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- MedImmune LLC
Glioma, Tumor
A First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma
The goal of this clinical trial is to collect data on the use of the CIPHER System when used by a surgeon during brain tumor removal.
- Conditions
- Glioma, Tumor, Electrocorticography, Brain
- Trial name
- CIPHER (NCT07465796)
- Testing
- Electrocorticography for neural recording, Electrocorticography for neural recording and electrical stimulation
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Coherence Neuro Australia Pty Limited
Breast Cancer
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
This is a multicenter phase 2 study designed to evaluate the safety and efficacy of eribulin mesylate in combination with trastuzumab as first line treatment in female subjects with locally recurrent or metastatic human epidermal…
- Trial name
- NCT01269346
- Testing
- Eribulin Mesylate
- Where
- 26 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eisai Inc.
Breast Cancer
A Retrospective Breast Reconstruction Study
To collect data on patients who have previously undergone breast reconstruction utilizing SimpliDerm and other HADMs.
- Trial name
- NCT04060134
- Testing
- SimpliDerm HADM, AlloDerm HADM, AlloMax HADM
- Where
- 5 sites in United States
- Volunteers
- 223 people
- Sponsor
- Elutia Inc.
Advanced Cancer
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
The purpose of this study is to assess the safety and tolerability of BMS-986406 administered alone, in combination with nivolumab, or in combination with nivolumab and platinum-doublet chemotherapy (PDCT) in participants with…
- Trial name
- NCT05298592
- Testing
- BMS-986406, Nivolumab, Carboplatin
- Where
- 29 sites in United States, Argentina and 4 more
- Volunteers
- 77 people
- Sponsor
- Bristol-Myers Squibb
Urothelial Cancer, GastroEsophageal Cancer
A Study of MGC030 in Participants With Advanced Solid Tumors
The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of MGC030.
- Conditions
- Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT07822399
- Testing
- MGC030
- Where
- United States
- Volunteers
- 314 people
- Sponsor
- MacroGenics
Neoplasms, Melanoma
Study of ASN003 in Subjects With Advanced Solid Tumors
The study is divided into two parts. The first part of the study will test various doses of ASN003 to find out the highest safe dose to test in three specific groups.
- Conditions
- Neoplasms, Melanoma, Colorectal Neoplasm, Carcinoma, Non-small Cell Lung
- Trial name
- NCT02961283
- Testing
- ASN003 ascending doses, ASN003 MTD
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Asana BioSciences
HTLV-I Infections, HTLV-II Infections
Evaluation of the MP Diagnostics HTLV Blot 2.4
The purpose of this study is: 1. To assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4. 2. To conduct a sensitivity analysis of the HTLV Blot 2.4 using a known positive population.
- Conditions
- HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2
- Trial name
- NCT01467024
- Testing
- CDPHL Algorithm
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- MP Biomedicals, LLC
Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma
This is an open label, first-in-man clinical trial to assess safety and tolerability of CEB-01 PLGA membrane in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma after surgery.
- Trial name
- NCT04619056
- Testing
- CEB-01 membrane loaded with SN-38
- Where
- 5 sites in Spain
- Volunteers
- 21 people
- Sponsor
- CEBIOTEX
Breast Cancer Female, Breast Cancer Prevent
First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer
This study is a first in human, two-stage single arm non-comparative study of safety and performance. The aim of the study is to asses the safety and the clinical performance of a new device : the MATTISSE tissu engineering…
- Conditions
- Breast Cancer Female, Breast Cancer Prevent, Breast Reconstruction
- Trial name
- TIDE (NCT05460780)
- Testing
- MATTISSE TEC
- Where
- 3 sites in France, Georgia
- Volunteers
- 50 people
- Sponsor
- Quanta Medical
Acute Lymphoblastic Leukemia
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
To evaluate the safety and tolerability of Human CD19-CD22 Targeted T Cells Injection for the treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
- Trial name
- NCT05223686
- Testing
- Human CD19-CD22 Targeted T Cells Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).
- Trial name
- NCT00994123
- Testing
- MM-121, Erlotinib
- Where
- 38 sites in United States, Canada and 4 more
- Volunteers
- 162 people
- Sponsor
- Merrimack Pharmaceuticals
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP).
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma
- Trial name
- EPITOME-1015-I (NCT06748872)
- Testing
- Lymphodepletion, TCR-T cells (MDG1015)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Medigene AG
Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and…
- Trial name
- NCT06665100
- Testing
- PUL-042
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Pulmotect, Inc.
Colorectal Cancer
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
The purpose of this first in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors.
- Trial name
- NCT05464030
- Testing
- M9140, Bevacizumab, Capecitabine
- Where
- 35 sites in United States, Canada and 3 more
- Volunteers
- 220 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.